Ambeed.cn

首页 / / / / Saracatinib

塞卡替尼 /Saracatinib {[allProObj[0].p_purity_real_show]}

货号:A154045 同义名: AZD0530

Saracatinib(AZD0530)是一种高效的Src家族抑制剂,对c-SrcLck、c-YESLynFyn、Fgr和Blk的IC50范围为2.7至11 nM,显示出对其他酪氨酸激酶的高选择性。

Saracatinib 化学结构 CAS号:379231-04-6
Saracatinib 化学结构
CAS号:379231-04-6
Saracatinib 3D分子结构
CAS号:379231-04-6
Saracatinib 化学结构 CAS号:379231-04-6
Saracatinib 3D分子结构 CAS号:379231-04-6
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price) ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price) ]}
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} 现货 咨询 - +
购物车0 收藏 询单

Saracatinib 纯度/质量文件 产品仅供科研

货号:A154045 标准纯度: {[allProObj[0].p_purity_real_show]}
批次查询: 批次纯度:

全球学术期刊中引用的产品

JMC, 2024. Ambeed. [ A919389 , A918471 , A995972 ]
Anal. Chem., 2024, 96(50): 19947-19954. Ambeed. [ A261947 , A1165388 ]
ACS Biomater. Sci. Eng., 2024. Ambeed. [ A220462 ]
ACS Biomater. Sci. Eng., 2024. Ambeed. [ A165235 , A110205 ]
Pharmaceutics, 2024, 16(12): 1546. Ambeed. [ A272538 , A187261 , A691302 , A506702 ]
更多 >
产品名称 ALK1 ALK2 ALK3 ALK4 ALK6 Smad3 TGF-β TGFβRI/ALK5 TGFβRII 其他靶点 纯度
LDN193189 ++++

ALK1, IC50: 0.8 nM

++++

ALK2, IC50: 0.8 nM

+++

ALK3, IC50: 5.3 nM

+++

ALK6, IC50: 16.7 nM

99%+
LDN-212854 ++++

ALK1, IC50: 2.4 nM

++++

ALK2, IC50: 1.3 nM

+

ALK3, IC50: 85.8 nM

+

ALK4, IC50: 2133 nM

+

ALK5, IC50: 9276 nM

99%+
ML347 ++

ALK1, IC50: 46 nM

++

ALK2, IC50: 32 nM

98%
K02288 ++++

ALK1, IC50: 1.8 nM

++++

ALK2, IC50: 1.1 nM

++

ALK3, IC50: 34.4 nM

+++

ALK6, IC50: 6.4 nM

99%+
LDN-193189 dihydrochloride ++++

ALK1, IC50: 0.8 nM

++++

ALK2, IC50: 0.8 nM

+++

ALK3, IC50: 5.3 nM

+++

ALK6, IC50: 16.7 nM

99%
LDN-214117 ++

ALK2, IC50: 24 nM

98%
DMH-1 +

ALK2, IC50: 107.9 nM

99%+
SB-505124 +

ALK4, IC50: 129 nM

++

ALK5, IC50: 47 nM

99%+
Vactosertib +++

ALK4, IC50: 13 nM

+++

ALK5, IC50: 11 nM

99%+
Alantolactone 98%
SIS3 97%
Pirfenidone 98%
Hesperetin 97%
RepSox ++++

TGFβR1(ALK5), IC50: 4 nM

98%
GW788388 +++

ALK5, IC50: 18 nM

98%
LY364947 ++

TGFβRI, IC50: 59 nM

+

TGFβRII, IC50: 0.4 μM

98%
SD-208 ++

TGF-βRI (ALK5), IC50: 48 nM

99%
SB-525334 +++

TGFβR1(ALK5), IC50: 14.3 nM

99%+
LY2109761 ++

TβRI, Ki: 38 nM

+

TβRII, Ki: 300 nM

99%+
Galunisertib ++

TβRI, IC50: 56 nM

98%
SB 431542 +

ALK5, IC50: 94 nM

99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。
产品名称 Abl Bcr-Abl 其他靶点 纯度
NVP-BHG 712 +

c-Abl, IC50: 1.667 μM

99%+
KW-2449 +++

Abl (T315I), IC50: 4 nM

Abl, IC50: 14 nM

FLT3 99%+
Ponatinib ++++

Abl, IC50: 0.37 nM

98%
AT9283 99%+
Imatinib Mesylate +

v-Abl, IC50: 600 nM

PDGFR,c-Kit 99%
Danusertib ++

Abl, IC50: 25 nM

RET 99%+
Rebastinib ++++

p-Abl1 (native), IC50: 0.75 nM

u-Abl1 (T315I), IC50: 5 nM

FLT3,Tie-2 99%+
PP121 ++

Abl, IC50: 18 nM

PDGFR,VEGFR 99%+
GNF-7 +++

M351T, IC50: 133 nM

E255V, IC50: 122 nM

99%+
Olverembatinib dimesylate ++++

Abl, IC50: 0.34 nM

Abl (G250E), IC50: 0.35 nM

99%
Dasatinib monohydrate ++++

Abl , IC50: 0.6 nM

Src 98%
Dasatinib ++++

Abl, IC50: 0.6 nM

Src 98%
Bafetinib +++

Abl, IC50: 5.8 nM

98+%
GNF-2 +

Bcr-Abl (K562 cell line), IC50: 273 nM

Bcr-Abl (SUP-B15 cell line), IC50: 268 nM

98%+
Degrasyn +

Bcr-Abl, IC50: 1.8 μM

DUB 98+%
GNF-5 ++

Bcr-Abl, IC50: 220 nM

99%
Radotinib ++

BCR-ABL1, IC50: 34 nM

98+%
PD173955 Src 99%+
Nilotinib ++

Bcr-Abl, IC50: <30 nM

98%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。
产品名称 Fyn Lck Lyn Src Yes 其他靶点 纯度
Saracatinib ++

Fyn, IC50: 10 nM

++++

LCK, IC50: <4 nM

+++

Lyn, IC50: 5 nM

++++

c-Src, IC50: 2.7 nM

99%+
SU6656 +

Fyn, IC50: 170 nM

+

Lyn, IC50: 130 nM

+

Src, IC50: 280 nM

++

YES, IC50: 20 nM

98%
PP1 +++

Fyn, IC50: 6 nM

+++

LCK, IC50: 5 nM

EGFR 99%+
PP2 +++

Fyn, IC50: 5 nM

++++

LCK, IC50: 4 nM

98%
WH-4-023 ++++

Lck, IC50: 2 nM

+++

Src, IC50: 6 nM

99%+
NVP-BHG 712 +

c-Src, IC50: 1.266 μM

99%+
CCT196969 ++

LCK, IC50: 0.02 μM

+

Src, IC50: 0.03 μM

98%
MNS +

Src, IC50: 29.3 μM

Syk,p97 98%
Tirbanibulin ++

Src (HuH7), GI50: 13 nM

Src (Hep 3B), GI50: 26 nM

99%+
PP121 ++

Src, IC50: 14 nM

PDGFR,VEGFR 99%+
Bosutinib ++++

Src, IC50: 1.2 nM

99%
Dasatinib monohydrate ++++

Src, IC50: 0.8 nM

98%
Quercetin Sirtuin,PKC 97%
Dasatinib ++++

Src, IC50: 0.8 nM

98%
Repotrectinib +++

Src, IC50: 5.3 nM

99%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。

Saracatinib 生物活性

靶点
  • EGFR/ErbB1

    EGFR (L861Q), IC50:4 nM

    EGFR, IC50:5 nM

  • Fyn

    Fyn, IC50:10 nM

  • Src

    c-Src, IC50:2.7 nM

  • Lck

    LCK, IC50:<4 nM

  • Lyn

    Lyn, IC50:5 nM

描述 Saracatinib is a potent Src inhibitor with IC50 of 2.7 nM, and potent to c-Yes, Fyn, Lyn, Blk, Fgr and Lck and is less active for Abl and EGFR (L858R and L861Q).

Saracatinib 细胞研究

细胞系 浓度 检测类型 检测时间 活动说明 数据源
697 Growth Inhibition Assay IC50=13.2701 μM SANGER
A253 Growth Inhibition Assay IC50=35.7429 μM SANGER
A388 Growth Inhibition Assay IC50=5.63667 μM SANGER
A704 Growth Inhibition Assay IC50=0.8921 μM SANGER

Saracatinib 临床研究

NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT01144481 - Completed - Canada, Ontario ... 展开 >> University Health Network Toronto, Ontario, Canada, M5G 2C4 收起 <<
NCT00265876 Pancreatic Cancer Phase 1 Phase 2 Completed - Canada, British Columbia ... 展开 >> BCCA - Vancouver Cancer Centre Vancouver, British Columbia, Canada, V5Z 4E6 Canada, Ontario Ottawa Health Research Institute - General Division Ottawa, Ontario, Canada, K1H 8L6 Algoma District Cancer Program Sault Ste. Marie, Ontario, Canada, P6B 0A8 Univ. Health Network-Princess Margaret Hospital Toronto, Ontario, Canada, M5G 2M9 收起 <<
NCT01000896 Cancer Non Sm... 展开 >>all Cell Lung Cancer Epithelial Ovarian Cancer 收起 << Phase 1 Withdrawn(AstraZeneca has disc... 展开 >>ontinued the development of AZD0530. No new AstraZeneca-sponsored clinical studies will be initiated..) 收起 << March 2011 Japan ... 展开 >> Research Site Matsuyama, Ehime, Japan Research Site Fukuoka, Japan 收起 <<

Saracatinib 参考文献

[1]Green TP, Fennell M, et al. Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530. Mol Oncol. 2009 Jun;3(3):248-61.

[2]Chang YM, Bai L, et al. Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530. Oncogene. 2008 Oct 23;27(49):6365-75.

Saracatinib 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.84mL

0.37mL

0.18mL

9.22mL

1.84mL

0.92mL

18.45mL

3.69mL

1.84mL

Saracatinib 技术信息

CAS号379231-04-6
分子式C27H32ClN5O5
分子量 542.027
别名 AZD0530
运输蓝冰
存储条件

In solvent -20°C:3-6个月-80°C:12个月

Pure form Keep in dark place,Sealed in dry,2-8°C

溶解度

DMSO: 50 mg/mL(92.25 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

动物实验配方

IP 2% DMSO+2% Tween80+40% PEG300+water 10 mg/mL clear

PO 0.5% CMC-Na 55 mg/mL suspension

Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
  • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务,不为任何个人或者非科研性质用途提供服务。